CALA News and Press, Calithera Biosciences Inc. From 10/29/20

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...

Gainers: Cleveland BioLabs (CBLI) +96%, Anchiano Therapeutics (ANCN) +46%, Aptinyx (APTX) +45%, SOS (SOS) +21%, Liquidia Technologies (LQDA) +18%.Losers: Baudax Bio (BXRX) -37%, BOQI International Medical (BIMI) -13%, Midatech Pharma (MTP) -11...

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Calithera initiates Phase 2 trial for lung cancer treatment. Vertex receives FDA approval for cystic fibrosis treatment. IGM Biosciences makes a deal with AbCellera for antibody discovery. For further details see: Calithera Lung Cancer Trial, And Other News: The Good, Ba...

Calithera Biosciences (CALA) has commenced Phase 2 (KEAPSAKE) trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed.The 120-subject study will evaluate the safety and investigator-assessed progression-free survival of...

- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard - of - care treatment in front-line setting among patients with non-small cell lung cancer and a mutation in the KEAP1 /NRF2 pathway ...

Calithera signals terminating partnership with Incyte Calithera Biosciences Inc. ( CALA ) reported that it has sent a written intimation to Incyte ( INCY ) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entere...

Calithera Biosciences (NASDAQ: CALA ) discloses that it has delivered written notice to Incyte (NASDAQ: INCY ) terminating their January 2017 collaboration and license agreement effective September 30. More news on: Calithera Biosciences, Inc., Incyte Corporation, Healthcare stocks...

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

Image source: The Motley Fool. Calithera Biosciences Inc   (NASDAQ: CALA) Q2 2020 Earnings Call Aug 10, 2020 , 5:00 p.m. ET Operator Continue reading